# OnCo record rhovac (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/rhovac/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "rhovac" ;
  schema:name "RhoVac"@en ;
  schema:alternateName "RhoVac AB"@en, "Chosa Oncology"@en ;
  schema:description "RhoVac was a Swedish biotech whose peptide vaccine RV001 trained T cells against RhoC, a protein of spreading cancer cells, but its phase 2b trial in prostate cancer failed in 2022."@en ;
  schema:url <https://onco.cc/companies/rhovac/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:tag "drug-maker" ;
  schema:addressCountry "SE" ;
  onco:drugs <https://onco.cc/drugs/rv001v/> .